Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Profit After Tax (2016 - 2025)

Cytosorbents' Profit After Tax history spans 15 years, with the latest figure at -$5.5 million for Q4 2025.

  • Quarterly results put Profit After Tax at -$5.5 million for Q4 2025, up 27.36% from a year ago — trailing twelve months through Dec 2025 was -$8.2 million (up 60.43% YoY), and the annual figure for FY2025 was -$8.2 million, up 60.43%.
  • Profit After Tax for Q4 2025 was -$5.5 million at Cytosorbents, down from -$3.2 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $15.3 million in Q4 2023 to a low of -$12.2 million in Q3 2022.
  • The 5-year median for Profit After Tax is -$5.8 million (2024), against an average of -$4.7 million.
  • The sharpest move saw Profit After Tax plummeted 1273.27% in 2021, then soared 2102.15% in 2023.
  • Year by year, Profit After Tax stood at -$9.3 million in 2021, then skyrocketed by 91.77% to -$766126.0 in 2022, then soared by 2102.15% to $15.3 million in 2023, then plummeted by 149.33% to -$7.6 million in 2024, then rose by 27.36% to -$5.5 million in 2025.
  • According to Business Quant data, Profit After Tax over the past three periods came in at -$5.5 million, -$3.2 million, and $1.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.